S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization

被引:25
|
作者
Dekeyne, Anne [1 ]
Brocco, Mauricette [1 ]
Loiseau, Florence [1 ]
Gobert, Alain [1 ]
Rivet, Jean-Michel [1 ]
Di Cara, Benjamin [1 ]
Cremers, Thomas I. [3 ]
Flik, Gunnar [3 ]
Fone, Kevin C. F. [4 ]
Watson, David J. G. [4 ]
Papp, Mariusz [5 ]
Sharp, Trevor [6 ]
Serres, Florence [6 ]
Cespuglio, Raymond [8 ]
Olivier, Berend [7 ]
Chan, Johnny S. W. [7 ]
Lavielle, Gilbert [2 ]
Millan, Mark J. [1 ]
机构
[1] Ctr Rech Croissy, Inst Rech Servier, Dept Psychopharmacol, Paris, France
[2] Ctr Rech Croissy, Inst Rech Servier, Dept Chem, Paris, France
[3] Brains On Line, Groningen, Netherlands
[4] Univ Nottingham, Inst Neurosci, Sch Biomed Sci, Nottingham NG7 2RD, England
[5] Polish Acad Sci, Inst Pharmacol, Krakow, Poland
[6] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[7] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[8] Univ Lyon 1, Fac Med, F-69365 Lyon, France
关键词
FREELY-MOVING RATS; PREFRONTAL CORTEX; NEUROTROPHIC FACTOR; RECOGNITION-MEMORY; SEXUAL DYSFUNCTION; 5-HT2C RECEPTORS; ANXIETY-LIKE; SLEEP; DEPRESSION; MODEL;
D O I
10.1124/jpet.111.187534
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present studies characterized the functional profile of N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo[e]indole-3-carboxamide) (S32212), a combined serotonin (5-HT)(2C) receptor inverse agonist and alpha(2)-adrenoceptor antagonist that also possesses 5-HT2A antagonist properties (J Pharmacol Exp Ther 340: 750-764, 2012). Upon parenteral and/or oral administration, dose-dependent (0.63-40.0 mg/kg) actions were observed in diverse procedures. Both acute and subchronic administration of S32212 reduced immobility time in a forced-swim test in rats. Acutely, it also suppressed marble burying and aggressive behavior in mice. Longterm administration of S32212 was associated with rapid (1 week) and sustained (5 weeks) normalization of sucrose intake in rats exposed to chronic mild stress and with elevated levels of mRNA encoding brain-derived neurotrophic factor in hippocampus and amygdala (2 weeks). S32212 accelerated the firing rate of adrenergic perikarya in the locus coeruleus and elevated dialysis levels of nor-adrenaline in the frontal cortex and hippocampus of freely moving rats. S32212 also elevated the frontocortical levels of dopamine and acetylcholine, whereas 5-HT, amino acids, and histamine were unaffected. These neurochemical actions were paralleled by "promnemonic" properties: blockade of scopolamine-induced deficits in radial maze performance and social recognition and reversal of delay-induced impairments in social recognition, social novelty discrimination, and novel object recognition. It also showed anxiolytic actions in a Vogel conflict procedure. Furthermore, in an electroencephalographic study of sleep architecture, S32212 enhanced slow-wave and rapid eye movement sleep, while decreasing waking. Finally, chronic administration of S32212 neither elevated body weight nor perturbed sexual behavior in male rats. In conclusion, S32212 displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance.
引用
收藏
页码:765 / 780
页数:16
相关论文
共 18 条
  • [1] S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2- Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization
    Millan, Mark J.
    la Cour, Clotilde Mannoury
    Chanrion, Benjamin
    Dupuis, Delphine S.
    Di Cara, Benjamin
    Audinot, Valerie
    Cussac, Didier
    Newman-Tancredi, Adrian
    Kamal, Maud
    Boutin, Jean A.
    Jockers, Ralf
    Marin, Philippe
    Bockaert, Joel
    Muller, Olivier
    Dekeyne, Anne
    Lavielle, Gilbert
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 340 (03): : 750 - 764
  • [2] Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist
    Gao, Nana
    Tiliwaerde, Murezati
    Zheng, Wei
    Xiong, Jie
    Li, Xiaorong
    Jin, Zengliang
    NEUROPHARMACOLOGY, 2021, 182
  • [3] Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule
    Aparici, Monica
    Carcasona, Carla
    Ramos, Israel
    Luis Montero, Jose
    Luis Ortiz, Jose
    Cortijo, Julio
    Puig, Carlos
    Vilella, Dolors
    Doe, Chris
    Gayalda, Amadeu
    Miralpeix, Montserrat
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 : 1 - 10
  • [4] A Novel Aminotetralin-Type Serotonin (5-HT)2C Receptor-Specific Agonist and 5-HT2A Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses
    Canal, Clinton E.
    Morgan, Drake
    Felsing, Daniel
    Kondabolu, Krishnakanth
    Rowland, Neil E.
    Robertson, Kimberly L.
    Sakhuja, Rajeev
    Booth, Raymond G.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 349 (02): : 310 - 318
  • [5] Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor.: II.: Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor
    Newman-Tancredi, A
    Cussac, D
    Audinot, V
    Nicolas, JP
    De Ceuninck, F
    Boutin, JA
    Millan, MJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (02): : 805 - 814
  • [6] Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture
    Amandine Descamps
    Colette Rousset
    Mark Millan
    Michael Spedding
    Philippe Delagrange
    Raymond Cespuglio
    Psychopharmacology, 2009, 205 : 93 - 106
  • [7] Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture
    Amandine Descamps
    Colette Rousset
    Mark J. Millan
    Michael Spedding
    Philippe Delagrange
    Raymond Cespuglio
    Psychopharmacology, 2009, 205 (1) : 175 - 175
  • [8] Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture
    Descamps, Amandine
    Rousset, Colette
    Millan, Mark
    Spedding, Michael
    Delagrange, Philippe
    Cespuglio, Raymond
    PSYCHOPHARMACOLOGY, 2009, 205 (01) : 93 - 106
  • [9] The β2-adrenoceptor agonist clenbuterol induces IL-1 receptor antagonist and IL-1 type II receptor expression in rat brain in vivo: implications for CNS inflammation
    McNamee, E. N.
    Tanveer, R.
    Ryan, K. M.
    Griffin, E.
    O'Sullivan, J. B.
    Harkin, A.
    Connor, T. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 573 - 573
  • [10] A Novel Aminotetralin-Type Serotonin (5-HT) 2C Receptor-Specific Agonist and 5-HT2A Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses (vol 349, pg 310, 2014)
    Canal, C. E.
    Morgan, D.
    Felsing, D.
    Kondabolu, K.
    Rowland, N. E.
    Robertson, K. L.
    Sakhuja, R.
    Booth, R. G.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 349 (03): : 533 - 533